Lilly’s Cyramza Wins Slim Nod, But Steba’s Tookad Falls Hard At US FDA Panel

 
• By Sue Sutter

Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.

FDA Advisory Committee Feature image
AdComm endorsed Cyramza labeling expansion by slimmest of margins but overwhelmingly recommended against Tookad's approval.

More from US FDA Performance Tracker

More from Regulatory Trackers